Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.
Adjuvants, Immunologic
/ pharmacology
Animals
Chromatography, High Pressure Liquid
Drug Delivery Systems
Haptens
/ drug effects
Humans
Immunity
/ drug effects
Interleukin-1beta
/ genetics
Mice
Nicotine
/ immunology
Peptides
/ immunology
Substance-Related Disorders
/ genetics
Tobacco Use Disorder
/ genetics
Vaccines, Conjugate
/ immunology
Vaccines, Subunit
/ immunology
IL-1β
bacterial derived adjuvant
dendritic cells
immune responses
macrophages
non-natural peptides
peptide solid phase synthesis
phagocytic cells
vaccine delivery
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
12 Mar 2020
12 Mar 2020
Historique:
received:
13
02
2020
revised:
05
03
2020
accepted:
07
03
2020
entrez:
18
3
2020
pubmed:
18
3
2020
medline:
18
12
2020
Statut:
epublish
Résumé
The addictive nature of nicotine is likely the most significant reason for the continued prevalence of tobacco smoking despite the widespread reports of its negative health effects. Nicotine vaccines are an alternative to the currently available smoking cessation treatments, which have limited efficacy. However, the nicotine hapten is non-immunogenic, and successful vaccine formulations to treat nicotine addiction require both effective adjuvants and delivery systems. The immunomodulatory properties of short, non-natural peptide sequences not found in human systems and their ability to improve vaccine efficacy continue to be reported. The aim of this study was to determine if small "non-natural peptides," as part of a conjugate nicotine vaccine, could improve immune responses. Four peptides were synthesized via solid phase methodology, purified, and characterized.
Identifiants
pubmed: 32178357
pii: molecules25061290
doi: 10.3390/molecules25061290
pmc: PMC7143940
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Haptens
0
IL1B protein, mouse
0
Interleukin-1beta
0
Peptides
0
Vaccines, Conjugate
0
Vaccines, Subunit
0
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Grand Challenges Canada
ID : S4-0212-01
Organisme : Northern Cancer Foundation
ID : 2013-2015
Organisme : CIHR
ID : PJT-148531
Pays : Canada
Organisme : Natural Sciences and Engineering Research Council of Canada
ID : Research Tools and Instruments Program
Organisme : Canadian Foundation for Innovation
ID : Leaders Opportunity Fund
Références
Nanomedicine. 2018 Jul;14(5):1655-1665
pubmed: 29719216
Biomaterials. 2017 Sep;138:46-56
pubmed: 28551462
Amino Acids. 2007 Nov;33(4):703-7
pubmed: 17077961
Heliyon. 2016 Aug 26;2(8):e00147
pubmed: 27622215
Chem Soc Rev. 2018 May 21;47(10):3659-3720
pubmed: 29697126
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7119-24
pubmed: 19359475
Bioorg Med Chem. 2018 Jun 1;26(10):2700-2707
pubmed: 28720325
PLoS One. 2019 Aug 23;14(8):e0221708
pubmed: 31442285
Biotechnol Annu Rev. 2008;14:109-41
pubmed: 18606361
Eur J Immunol. 2004 Apr;34(4):1085-90
pubmed: 15048719
Mol Cell. 2002 Aug;10(2):417-26
pubmed: 12191486
J Med Chem. 2003 Jul 3;46(14):3094-101
pubmed: 12825947
Expert Opin Drug Discov. 2016 Dec;11(12):1151-1163
pubmed: 27718641
Hum Gene Ther. 2010 Dec;21(12):1687-96
pubmed: 20583863
Int J Mol Med. 2015 Jan;35(1):17-23
pubmed: 25395173
Mol Pharm. 2019 Apr 1;16(4):1467-1476
pubmed: 30821985
Cancer Immunol Res. 2017 Jan;5(1):72-83
pubmed: 27941004
J Immunol. 1999 May 15;162(10):6141-7
pubmed: 10229857
J Pharmacol Exp Ther. 2004 Apr;309(1):146-55
pubmed: 14718586
Hum Vaccin Immunother. 2013 Apr;9(4):808-11
pubmed: 23563510
Drug Discov Today. 2015 Jan;20(1):122-8
pubmed: 25450771
FEMS Immunol Med Microbiol. 2012 Jul;65(2):270-82
pubmed: 22333034
Pharmacol Rev. 2017 Jul;69(3):298-315
pubmed: 28634286
PLoS One. 2018 Sep 27;13(9):e0204472
pubmed: 30260999
Vaccine. 2010 Nov 3;28(47):7556-62
pubmed: 20800114
Adv Pharmacol. 2014;69:553-80
pubmed: 24484987
Protein Pept Lett. 2018;25(10):924-932
pubmed: 30255740
Vaccines (Basel). 2017 May 17;5(2):
pubmed: 28513561
Biomaterials. 2018 Feb;155:165-175
pubmed: 29179132
Vaccine. 2010 Oct 4;28(42):6901-14
pubmed: 20723629
PLoS One. 2012;7(8):e43802
pubmed: 22937099
Oncoimmunology. 2018 Sep 6;7(12):e1511506
pubmed: 30524907
Int Immunopharmacol. 2015 Dec;29(2):663-671
pubmed: 26404190
Curr Opin Pharmacol. 2019 Aug;47:20-26
pubmed: 30831470
Nanomedicine (Lond). 2014 Dec;9(17):2657-69
pubmed: 25529569
Protein Sci. 2007 Oct;16(10):2251-9
pubmed: 17893362
Ann N Y Acad Sci. 2010 Dec;1213:46-61
pubmed: 20946578
Vaccine. 2019 Mar 14;37(12):1584-1590
pubmed: 30772068
Virology. 2018 Feb;515:21-28
pubmed: 29223787
Vaccines (Basel). 2019 Sep 02;7(3):
pubmed: 31480779
Annu Rev Immunol. 2009;27:519-50
pubmed: 19302047